CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing topical kinase inhibitors for inflammatory diseases like psoriasis and atopic dermatitis. By utilizing a proprietary technology that minimizes systemic absorption, it aims to create effective treatments with reduced side effects.
Over the last decade, kinases have emerged as attractive therapeutic targets in inflammatory diseases.
Numerous efforts in the pharmaceutical community are directed towards the discovery of small molecule inhibitors that regulate kinase function.A number of issues need to be addressed when considering kinases as targets in inflammation.
The combination of efficacy and favourable safety profile is often key for the successful treatment of chronic inflammatory and/or autoimmune diseases with kinas…
CREABILIS THERAPEUTICS SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Torviscosa
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
NETHERLANDS ORGANISATION FORAPPLIED SCIENTIFIC RESEARCH
Netherlands, Den Haag
Type: Research institute
Activity type: Research Organisations
SME: No
United Kingdom, Dundee
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, ZEIST
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
